Information Provided By:
Fly News Breaks for March 12, 2019
Mar 12, 2019 | 09:33 EDT
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Trillium Therapeutics to $4 from $10 citing dilution from the recent capital raise and potential fund raises in the future. However, first look clinical results for TTI-622 in the second half of 2019 "could be a major catalyst for the stock," Ramakanth tells investors in a research note. He reiterates a Buy rating on the shares.
News For TRIL From the Last 2 Days
There are no results for your query TRIL